|
|
| (One intermediate revision by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Labetalol#Drug Interactions]] |
| {{Labetalol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| In one survey, 2.3% of patients taking labetalol HCl in combination with[[ tricyclic antidepressants]] experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone. The contribution of each of the treatments to this adverse reaction is unknown, but the possibility of a drug interaction cannot be excluded.
| |
| | |
| Drugs possessing beta-blocking properties can blunt the [[bronchodilator]] effect of beta-receptor agonist drugs in patients with bronchospasm; therefore, doses greater than the normal antiasthmatic dose of beta-agonist [[bronchodilator]] drugs may be required.
| |
| [[Cimetidine]] has been shown to increase the bioavailability of labetalol HCl. Since this could be explained either by enhanced absorption or by an alteration of hepatic metabolism of labetalol HCl, special care should be used in establishing the dose required for blood pressure control in such patients.
| |
| | |
| Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl. During controlled hypotensive anesthesia using labetalol HCl in association with [[halothane]], high concentrations (3% or above) of [[halothane]] should not be used because the degree of [[hypotension ]]will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure. The anesthesiologist should be informed when a patient is receiving labetalol HCl.
| |
| | |
| Labetalol HCl blunts the reflex [[tachycardia]] produced by [[nitroglycerin]] without preventing its [[hypotensive]] effect. If labetalol HCl is used with [[nitroglycerin]] in patients with [[angina]] pectoris, additional [[antihypertensive]] effects may occur. | |
| | |
| Care should be taken if labetalol is used concomitantly with calcium antagonists of the [[verapamil]] type.
| |
| Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate.Concomitant use can increase the risk of [[bradycardia]].
| |
| '''Risk of Anaphylactic Reaction''': While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of [[epinephrine]]used to treat allergic reaction.
| |
| | |
| ===Drug & OR Laboratory Test Interactions===
| |
| | |
| The presence of labetalol metabolites in the urine may result in falsely elevated levels of urinary [[catecholamine]]s, [[metanephrine]], [[normetanephrine]], and [[vanillylmandelic acid]] when measured by fluorimetric or photometric methods. In screening patients suspected of having a [[pheochromocytoma]] and being treated with labetalol HCl, a specific method, such as a high performance liquid chromatographic assay with solid phase extraction (e.g., J Chromatogr 385:241,1987) should be employed in determining levels of [[catecholamine]]s.
| |
| | |
| Labetalol HCl has also been reported to produce a false-positive test for [[amphetamine]] when screening urine for the presence of drugs using the commercially available assay methods Toxi-Lab A®(thin-layer chromatographic assay) and Emit-d.a.u ®(radioenzymatic assay). When patients being treated with labetalol have a positive urine test for amphetamine using these techniques, confirmation should be made by using more specific methods, such as a gas chromatographic-mass spectrometer technique.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LABETALOL HYDROCHLORIDE TABLET, FILM COATED [WATSON LABORATORIES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a5b65a9b-6b8a-48a4-9c72-0e605bb309eb | publisher = | date = | accessdate = 5 February 2014 }}</ref>
| |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
|
| |
|
| [[Category:Beta blockers]] | | [[Category:Beta blockers]] |
| Line 33: |
Line 5: |
| [[Category:Cardiovascular Drugs]] | | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |